Zobrazeno 1 - 10
of 127
pro vyhledávání: '"Mark A Samaan"'
Autor:
Raphael P Luber, Alexa Duff, Polychronis Pavlidis, Sailish Honap, Susanna Meade, Shuvra Ray, Simon H Anderson, Joel Mawdsley, Mark A Samaan, Peter M Irving
Publikováno v:
JGH Open, Vol 6, Iss 1, Pp 76-84 (2022)
Abstract Background and Aim Patients with chronic diseases are believed to be at increased risk of mental health conditions during the COVID‐19 pandemic. We aimed to assess the incidence of psychological morbidity in inflammatory bowel disease (IBD
Externí odkaz:
https://doaj.org/article/1083fc29a8d843a1b3bb2d0d1a90979f
Publikováno v:
BMJ Open Gastroenterology, Vol 9, Iss 1 (2022)
The WHO has recognised iron deficiency anaemia (IDA) as the most common nutritional deficiency in the world, with 30% of the population being affected with this condition. Although the most common causes of IDA are gastrointestinal bleeding and menst
Externí odkaz:
https://doaj.org/article/be36eddf923f421c9ad7a4b38ceb32a6
Autor:
Susanna Meade, Raphael P. Luber, Gokul Tamilarasan, Eoin Dinneen, Peter M. Irving, Mark A. Samaan
Publikováno v:
European Medical Journal, Vol 6, Iss 1, Pp 49-58 (2021)
It was predicted that the biological era might alter the natural history of Crohn’s disease, preventing the well-documented inflammation–fibrosis–fistulisation sequence. However, despite the development of novel biological therapies, average ef
Externí odkaz:
https://doaj.org/article/6372607202774489b7f85a62cf4b8cda
Autor:
Franco Torrente, Susanna Meade, Eric I Benchimol, Lissy de Ridder, Nicholas M Croft, Jochen Kammermeier, David R Mack, Renz C W Klomberg, Dan Turner, David C Wilson, Javier Martín-de-Carpi, Jiri Bronsky, Jorge Amil Dias, Gregor Walker, C Heleen van Ommen, Michael P Powar, Natasha Burgess, Peter M Irving, Mark A Samaan, Richard Hansen
Publikováno v:
Journal of Crohn's & colitis, 16(10), 1609-1616. Oxford University Press
JOURNAL OF CROHNS & COLITIS
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
JOURNAL OF CROHNS & COLITIS
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
Background and Aims Thromboprophylaxis use in paediatric inflammatory bowel disease [IBD] is inconsistent. Current guidelines only support treating children with acute severe colitis with risk factors. We convened an international RAND panel to explo
Autor:
Susanna Meade, Kamal V. Patel, Raphael P. Luber, Dearbhaile O'Hanlon, Andra Caracostea, Polychronis Pavlidis, Sailish Honap, Cheran Anandarajah, Nyree Griffin, Sebastian Zeki, Shuvra Ray, Joel Mawdsley, Mark A. Samaan, Simon H. Anderson, Amir Darakhshan, Katie Adams, Andrew Williams, Jeremy D. Sanderson, Miranda Lomer, Peter M. Irving
Publikováno v:
Alimentary Pharmacology & Therapeutics. 56:646-663
Low-quality evidence suggests that pre-operative exclusive enteral nutrition (E/EN) can improve postoperative outcomes in patients with Crohn's disease (CD). It is not standard practice in most centres.To test the hypothesis that pre-operative EN in
Autor:
Charles Miller, Hanson Kwok, Paul Harrow, Roser Vega, Edward Seward, Shameer Mehta, Farooq Rahman, Sara McCartney, Ioanna Parisi, Samuel Hsiang Lim, Esha Sharma, Mark A Samaan, Aaron Bancil, Klaartje Bel Kok, Ahmed Shalabi, Emma L Johnston, Dev Katarey, Nina Taherzadeh, Charles Murray, Mohammed Tauseef Sharip, Martyn J Carter, Shiva T Radhakrishnan, Simon Peake, Imran Khakoo, Mahmood Wahed, Sebastian Povlsen, Mehul Patel, Patrick DuBois, Jemima Finkel, Clive Onnie, Stuart Bloom
Publikováno v:
Frontline Gastroenterol
BackgroundSequential drug treatment with biological agents in ulcerative colitis (UC) is becoming increasingly complex. There are few studies comparing head-to-head outcomes in second-line treatments. The study assesses whether using anti-tumour necr
Publikováno v:
Journal of Crohn'scolitis.
Autor:
Sailish Honap, Peter M. Irving, Hajir Ibraheim, Mark A Samaan, Susanna Meade, Michael P. Jones
Publikováno v:
Digestive Diseases and Sciences. 67:1018-1035
Ustekinumab, an interleukin-12 and interleukin-23 antagonist, is licensed for the treatment of Crohn’s disease (CD) and ulcerative colitis (UC) after the phase III trial programs demonstrated efficacy over placebo. However, these findings may not b
Autor:
Andra Caracostea, Joel Mawdsley, Simon Anderson, Anna Stanton, Dearbhaile O’Hanlon, Shuvra Ray, Mark A Samaan, Sebastian Zeki, Polychronis Pavlidis, Sherill Tripoli, Esha Sharma, Sailish Honap, Peter M. Irving, Jeremy D. Sanderson, Alexa Duff, Susanna Meade, Rebecca Reynolds, Francesca D'Errico, Raphael P. Luber, Katie Hill
Publikováno v:
GastroHep
Gastrohep
Gastrohep
Background To quantify the effects of COVID‐19 on our inflammatory bowel disease (IBD) unit, including service provision, prescribing practices and use of therapeutic drug monitoring (TDM). Methods We performed a single centre retrospective observa
Publikováno v:
Alimentary pharmacologytherapeuticsREFERENCES. 55(6)